Dissemin is shutting down on January 1st, 2025

Published in

Wiley, ChemPlusChem, 5(88), 2023

DOI: 10.1002/cplu.202300028

Links

Tools

Export citation

Search in Google Scholar

Cysteine‐Based Perfluorinated Derivatives: A Theoretical and Experimental Study**

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

AbstractCysteine‐based perfluoroaromatic (hexafluorobenzene (HFB) and decafluorobiphenyl (DFBP)) were synthesized and established as a chemoselective and available core to construct molecular systems ranging from small molecules to biomolecules with interesting properties. The DFBP was found more effective than HFB for the monoalkylation of decorated thiol molecules. As proof of concept of the potential application of perfluorinated derivatives as non‐cleavable linkers, some antibody‐perfluorinated conjugates were prepared via thiol through two different strategies, i) using thiol from reduced cystamine coupling to carboxylic acids from mAb by amide bond, and ii) using thiols from reduction of mAb disulfide bond. Conjugates cell binding analysis demonstrated that the bioconjugation does not affect the macromolecular entity. Besides, some molecular properties of synthesized compounds are evaluated through spectroscopic characterization (FTIR and 19F NMR chemical shifts) and theoretical calculations. The comparison of calculated and experimental 19F NMR shifts and IR wavenumbers give excellent correlations, asserting as powerful tools in structurally identifying HFB and DFBP derivatives. Moreover, molecular docking was also developed to predict cysteine‐based perfluorated derivatives’ affinity against topoisomerase Il and cyclooxygenase 2 (COX‐2). The results suggested that mainly cysteine‐based DFBP derivatives could be potential topoisomerase II α and COX‐2 binders, becoming potential anticancer agents and candidates for anti‐inflammatory treatment.